July 08, 2024
2 min watch
On this video, Alexander Chehrazi-Raffle, MD, discusses the outcomes of the CHAARTED 2 cooperative group research into metastatic castration-resistant prostate most cancers, offered at ASCO Annual Assembly.
Chehrazi-Raffle, a medical oncologist on the Metropolis of Hope Duarte Most cancers Middle, mentioned the research, which studied cabazitaxel plus abiraterone versus abiraterone alone in sufferers who had beforehand progressed on docetaxel.
“The massive takeaway from CHAARTED 2 was that the mix of abiraterone plus cabazitaxel is price exploring as an alternative choice to [androgen receptor pathway inhibitors] plus docetaxel for a high-volume hormone-sensitive prostate most cancers, as a result of that mixture might afford a bit higher efficacy in comparison with the docetaxel plus abiraterone or docetaxel plus thalidomide choices which might be at present useful,” Chehrazi-Raffle stated.
